LAKEWOOD, Colo.--(BUSINESS WIRE)--CaridianBCT, a leading global provider of technology, products and services in the blood banking, transfusion medicine and cell therapy industries, today announced it will present results from a clinical study of CaridianBCT’s Mirasol® Pathogen Reduction Technology System for whole blood at the 2010 AABB Annual Meeting in Baltimore, Maryland. The study was a clinical trial for treating whole blood with the Mirasol Pathogen Reduction Technology (PRT) and was performed after receiving Investigational Device Exemption (IDE) approval from the U.S. Food and Drug Administration (FDA) and support from the U.S. Department of Defense (DoD).
